Pfizer Inc. (NYSE:PFE) Shares Acquired by Seelaus Asset Management LLC

Seelaus Asset Management LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 61.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,427 shares of the biopharmaceutical company’s stock after acquiring an additional 11,215 shares during the period. Seelaus Asset Management LLC’s holdings in Pfizer were worth $852,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Northcape Wealth Management LLC increased its stake in Pfizer by 1.8% during the 3rd quarter. Northcape Wealth Management LLC now owns 23,774 shares of the biopharmaceutical company’s stock worth $688,000 after buying an additional 419 shares during the period. Altrius Capital Management Inc boosted its position in Pfizer by 2.9% in the 3rd quarter. Altrius Capital Management Inc now owns 152,584 shares of the biopharmaceutical company’s stock valued at $4,416,000 after buying an additional 4,350 shares during the period. Bank of Marin grew its stake in shares of Pfizer by 17.4% in the third quarter. Bank of Marin now owns 8,430 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 1,250 shares in the last quarter. Valley Wealth Managers Inc. increased its position in shares of Pfizer by 4.5% during the third quarter. Valley Wealth Managers Inc. now owns 678,742 shares of the biopharmaceutical company’s stock worth $19,643,000 after acquiring an additional 28,933 shares during the period. Finally, Empowered Funds LLC raised its stake in shares of Pfizer by 80.9% in the third quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company’s stock valued at $14,709,000 after acquiring an additional 227,349 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE opened at $24.80 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The stock has a market cap of $140.54 billion, a PE ratio of 33.51, a price-to-earnings-growth ratio of 0.85 and a beta of 0.67. The firm has a fifty day moving average price of $28.64 and a 200 day moving average price of $28.64.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.77%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is currently 227.03%.

Analyst Ratings Changes

Several research analysts recently commented on PFE shares. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Wells Fargo & Company upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. UBS Group boosted their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eight have given a hold rating, five have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $32.92.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.